New lupus drug candidate enters early human safety testing
NCT ID NCT07306585
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new medicine called HC022 in 32 adults with lupus (SLE or CLE). The main goal is to see if the drug is safe and how the body handles it. Participants will receive multiple doses or a placebo, and researchers will monitor for side effects and measure drug levels in the blood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Drug combo quiet lupus kidney flares?
- Can a new antibody tame lupus flares?
- Could a single injection tame the immune system in lupus?
- Can a single infusion of reprogrammed immune cells quiet lupus kidney disease?
- Old malaria drug may tame lupus skin flares
- Eye tests could spot silent vision damage in lupus patients